Germany’s BioNTech expands by acquiring division of MAB Discovery

Germany-based biotech BioNTech some days ago made the headlines of many economic-financial dailies by announcing a probable IPO. The Mainz-based group has made the news again today by announcing it has acquired MAB Discovery’s division manufacturing antibodies. The deal means to BioNTech the availability of new ligands to develop new therapies through BioNTech’s RiboMABS® technology. The parties have not provided the financial details of the transaction.

(Source: BioNTech)